NASDAQ:AGENAgenus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Agenus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.50 +0.16 (+6.84 %) (As of 04/10/2020 06:05 AM ET) Add Compare Share Today's Range$2.35Now: $2.50▼$2.5450-Day Range$1.92MA: $2.56▼$4.3952-Week Range$1.82Now: $2.50▼$4.57Volume2.66 million shsAverage Volume2.27 million shsMarket Capitalization$403.98 millionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAgenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Agenus has a potential upside of 140.0% from its current price of $2.50.Amount of Analyst CoverageAgenus has received no research coverage in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAgenus has received 427 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAgenus has received 334 “underperform” votes. (Add your “underperform” vote.)Community SentimentAgenus has received 56.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote “Outperform” if you believe AGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAgenus does not currently pay a dividend.Dividend GrowthAgenus does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Agenus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Agenus is held by insiders.Percentage Held by InstitutionsOnly 33.82% of the stock of Agenus is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Agenus are expected to grow by 2.44% in the coming year, from ($1.23) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Agenus is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Agenus is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AGEN Previous Symbol CUSIP00847G70 CIK1098972 Webhttp://agenusbio.com/ Phone781-674-4400Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$150.05 million Price / Sales2.69 Cash FlowN/A Price / Cash FlowN/A Book Value($1.68) per share Price / Book-1.49Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-107,660,000.00 Net Margins-74.35% Return on EquityN/A Return on Assets-57.01%Miscellaneous Employees294 Outstanding Shares161,590,000Market Cap$403.98 million Next Earnings Date5/8/2020 (Estimated) OptionableOptionable Receive AGEN News and Ratings via Email Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AGEN Rates by TradingView Agenus (NASDAQ:AGEN) Frequently Asked Questions How has Agenus' stock been impacted by COVID-19 (Coronavirus)? Agenus' stock was trading at $2.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGEN shares have decreased by 8.1% and is now trading at $2.50. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Agenus? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agenus. When is Agenus' next earnings date? Agenus is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Agenus. How were Agenus' earnings last quarter? Agenus Inc (NASDAQ:AGEN) released its quarterly earnings results on Thursday, March, 12th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.38) by $0.16. The biotechnology company had revenue of $34.50 million for the quarter, compared to analyst estimates of $17.05 million. View Agenus' earnings history. What price target have analysts set for AGEN? 1 equities research analysts have issued 12-month target prices for Agenus' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Agenus' share price to reach $6.00 in the next year. This suggests a possible upside of 140.0% from the stock's current price. View analysts' price targets for Agenus. Has Agenus been receiving favorable news coverage? News articles about AGEN stock have been trending very negative on Friday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agenus earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutAgenus. Are investors shorting Agenus? Agenus saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 13,020,000 shares, an increase of 7.2% from the February 13th total of 12,150,000 shares. Based on an average daily volume of 1,720,000 shares, the days-to-cover ratio is presently 7.6 days. Approximately 12.4% of the company's stock are sold short. View Agenus' Current Options Chain. Who are some of Agenus' key competitors? Some companies that are related to Agenus include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Agenus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include Rosetta Genomics (ROSG), Exelixis (EXEL), REDHILL BIOPHAR/S (RDHL), Merrimack Pharmaceuticals (MACK), Opko Health (OPK), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Energy Transfer LP Unit (ET) and AcelRx Pharmaceuticals (ACRX). Who are Agenus' key executives? Agenus' management team includes the following people: Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)Dr. Jennifer Buell, Chief Operating OfficerDr. Alexander R. Duncan, CTO & Head of Research (Age 57)Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51)Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53) What is Agenus' stock symbol? Agenus trades on the NASDAQ under the ticker symbol "AGEN." How do I buy shares of Agenus? Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Agenus' stock price today? One share of AGEN stock can currently be purchased for approximately $2.50. How big of a company is Agenus? Agenus has a market capitalization of $403.98 million and generates $150.05 million in revenue each year. The biotechnology company earns $-107,660,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Agenus employs 294 workers across the globe. View additional information about Agenus. What is Agenus' official website? The official website for Agenus is http://agenusbio.com/. How can I contact Agenus? Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: Initial Coin Offerings entail a high degree of risk
